Oragenics Faces Delisting Concerns
Ticker: OGEN · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1174940
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Oragenics might get delisted, stock could tank.
AI Summary
On April 18, 2024, Oragenics, Inc. filed an 8-K report detailing its notice of delisting or failure to satisfy continued listing rules. The company is also addressing other events and filing financial statements and exhibits. The filing indicates potential issues with maintaining its listing on the stock exchange.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock value and investor confidence.
Risk Assessment
Risk Level: high — The filing explicitly mentions 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' indicating a significant risk to the company's stock market viability.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- April 18, 2024 (date) — Date of earliest event reported
- 1990 Main Street Suite 750 Sarasota, FL 34236 (address) — Principal executive offices
- 813-286-7900 (phone_number) — Registrant's telephone number
FAQ
What specific listing rule or standard has Oragenics, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Oragenics, Inc. has failed to satisfy, only that a notice has been issued.
What are the implications of this notice of delisting for Oragenics, Inc. shareholders?
A delisting would likely result in the company's stock trading on over-the-counter markets, potentially reducing liquidity and investor interest, and could lead to a significant decrease in stock value.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 18, 2024.
What is Oragenics, Inc.'s principal executive office address?
Oragenics, Inc.'s principal executive office is located at 1990 Main Street Suite 750, Sarasota, FL 34236.
Does this filing provide details on Oragenics, Inc.'s current financial condition?
While the filing mentions 'Financial Statements and Exhibits,' it primarily serves as a notice of delisting and other events, and does not provide a detailed analysis of the company's current financial condition within the provided text.
Filing Stats: 1,028 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-04-19 17:48:36
Key Financial Figures
- $4 million — company to have stockholders' equity of $4 million or more if the listed company has repor
- $6 million — company to have stockholders' equity of $6 million or more if the listed company has repor
- $3.2 million — Company reported stockholders equity of $3.2 million as of December 31, 2023, and losses fro
- $0.001 — any's shares of common stock, par value $0.001 per share (the "Common Stock"), which w
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-24-015404.txt ( ) — 241KB
- ogen-20240418.xsd (EX-101.SCH) — 3KB
- ogen-20240418_lab.xml (EX-101.LAB) — 33KB
- ogen-20240418_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19 th day of April, 2024. ORAGENICS, INC. (Registrant) BY: / s/ Janet Huffman Janet Huffman Chief Financial Officer